目的 評價加替沙星與左氧氟沙星治療泌尿系統(tǒng)感染的臨床安全性、有效性，及療效與成本。方法 檢索1998年1月-2016年4月在PubMed、Cochrane圖書館、中國期刊全文數(shù)據(jù)庫（CNKI）、萬方數(shù)據(jù)庫、中文科技期刊全文數(shù)據(jù)庫（VIP）、中國生物醫(yī)學(xué)文獻數(shù)據(jù)庫（CBM）發(fā)表的有關(guān)加替沙星與左氧氟沙星治療泌尿系統(tǒng)感染的文獻，按照Cochrane系統(tǒng)評價方法，運用Rev Man 4.2.10軟件進行Meta分析。結(jié)果 納入文獻17篇，共1 348例；加替沙星治療泌尿系統(tǒng)感染的有效性明顯高于左氧氟沙星[RR=2.01，95% CI（1.44、2.79）]，療程與不良反應(yīng)無差異[RR=0.76，95% CI（0.50、1.17），P=0.22]，但加替沙星治療泌尿系統(tǒng)感染的成本-效果明顯低于左氧氟沙星。結(jié)論 目前泌尿系統(tǒng)感染的治療方案中，盡管左氧氟沙星的療效稍遜色于加替沙星，但左氧氟沙星更具成本-效果優(yōu)勢。

Objective Evaluation of gatifloxacin and levofloxacin in the treatment of urinary tract infection clinical safety, effectiveness, efficiency, and cost of treatment. Methods Retrieving from January 1998 to April 2016 in PubMed, Cochrane Library, Chinese Journal Full-text Database (CNKI), Wanfang Database, Chinese Science and Technology Journal Full-text Database (VIP), Chinese Biomedical Literature Database (CBM) published on plus gatifloxacin and levofloxacin in the treatment of urinary tract infections in the literature, according to Cochrane systematic review methods, using Rev Man 4.2.10 Meta-analysis software. Results Document 17 included, a total of 1 348 cases; the effectiveness of gatifloxacin treatment of urinary tract infection was significantly higher than levofloxacin [RR=2.01, 95% CI (1.44, 2.79)], treatment and adverse indifference [RR=0.76, 95% CI (0.50, 1.17), P=0.22], but the cost of gatifloxacin treatment of urinary tract infection was significantly lower than the effect of levofloxacin. Conclusion Currently urinary tract infection treatment regimens, though the effectiveness of gatifloxacin was higher than levofloxacin, but levofloxacin more cost-effectiveness advantage.